RESUMO
The 'Stakeholder Perspectives on Noninvasive Prenatal Genetic Screening' Symposium was held in conjunction with the 2015 annual meeting of the International Society for Prenatal Diagnosis. During the day-long meeting, a panel of patient advocacy group (PAG) representatives discussed concerns and challenges raised by prenatal cell-free DNA (cfDNA) screening, which has resulted in larger demands upon PAGs from concerned patients receiving prenatal cfDNA screening results. Prominent concerns included confusion about the accuracy of cfDNA screening and a lack of patient education resources about genetic conditions included in cfDNA screens. Some of the challenges faced by PAGs included funding limitations, lack of consistently implemented standards of care and oversight, diverse perspectives among PAGs and questions about neutrality, and lack of access to training and genetic counselors. PAG representatives also put forward suggestions for addressing these challenges, including improving educational and PAG funding and increasing collaboration between PAGs and the medical community. © 2016 John Wiley & Sons, Ltd.
Assuntos
Transtornos Cromossômicos/diagnóstico , DNA/sangue , Organizações sem Fins Lucrativos , Defesa do Paciente , Diagnóstico Pré-Natal , Feminino , Aconselhamento Genético , Acessibilidade aos Serviços de Saúde , Humanos , Defesa do Paciente/economia , Defesa do Paciente/ética , Educação de Pacientes como Assunto/economia , Educação de Pacientes como Assunto/normas , Valor Preditivo dos Testes , Gravidez , Sensibilidade e Especificidade , Análise de Sequência de DNA , Padrão de Cuidado , Estados UnidosRESUMO
Drug shortages are not new; they have been managed through conservation, procurement of alternatives, and redistribution of stock The Sandoz shortage in 2012 has caused a radical reduction of generic injectables. In Newfoundland and Labrador, our response has led to the development of the framework, structure, and process outlined in this paper. The efforts have eased the concerns of clinicians and leaders, as they are aware of the decision-making resource for situations of drug and technology shortage.